


Prescription Pharmaceuticals Anti-Rheumatic Pharmaceuticals

Sales of *Rimatil*,
Azulfidine EN and *Metolate*



Rimatil, *Azulfidine EN* and *Metolate* are each highly recommended under the Guidelines for the Management of Rheumatoid Arthritis and as a result of their steadily expanding use as preferred treatment options, Santen's prescription anti-rheumatic pharmaceuticals net sales grew 2.6% to ¥9,627 million in fiscal 2007.

Net Sales ¥9,627 million +2.6%

The causes of rheumatoid arthritis (RA) are not yet well understood, but it is thought to be a chronic inflammatory disorder that affects the whole body. Inflammation occurs particularly in the joints, causing pain and swelling, and can often lead to bone and cartilage damage and subsequent joint deformity. It is estimated that there are approximately 700,000 people with RA in Japan today. The Japanese market for DMARDs* expanded 3.7%, to ¥24,100 million, in fiscal 2007, as the number of patients grew in line with population aging and prescriptions of higher-priced medications increased.

Santen has built its leading market share of the prescription anti-rheumatic pharmaceuticals market through active promotion of *Rimatil*, *Azulfidine EN* and *Metolate* in hospitals and clinics. Among sales results of core products in the period under review, *Rimatil* fell 3.0%, sales of *Azulfidine EN*, which displays early-onset effect characteristics, grew a favorable 6.0% year on year, and effective promotional activities propelled *Metolate*, launched in July 2004, to make good inroads in the market. As a result, net sales of prescription anti-rheumatic pharmaceuticals increased 2.6%, to ¥9,627 million, and Santen maintained its dominant position as leader of the DMARDs market, with a 46.1% share.

The Guidelines for the Management of Rheumatoid Arthritis, announced in April 2004 by the Japan College of Rheumatology, recommends treating RA with DMARDs from the early stages to improve patients' quality of life (QOL) by retarding the progress of joint destruction and so avoiding the development of joint deformity. Santen's *Rimatil*, *Azulfidine EN* and *Metolate* are each rated "Grade A – Highly Recommended" under the guidelines, which gives them a high profile as strongly recommended treatment options. To broaden the market share of these three products even further, we will continue to emphasize this solid independent support for their superior efficacy in our promotional activities.

* A class of medicines that are used not only to alleviate symptoms but also to treat the causes of disease. The anti-rheumatic effect works by calming inflammation through the correction of immune abnormalities, which are considered a cause of rheumatoid arthritis.

